Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals

Abstract

a single dose of MF59-adjuvanted 2009 influenza H1N1 vaccine induced an immune response against pandemic H1N1 virus in HIV-1-positive individuals reaching titers similar to those of HIV-1-negative individuals. The seroconversion rate was negatively associated with HIV infection and increasing age.

Cellular and Humoral Immune Responses to Pandemic Influenza Vaccine in Healthy and in Highly Active Antiretroviral Therapy-Treated HIV Patients

“…22,23 In contrast, other work has suggested a lower response in HIV-infected individuals, even in successfully treated patients. [18][19][20] It may be speculated that the apparent discrepancy is mainly attributable to the baseline level of reactivity to influenza virus antigen that is clearly higher in the HIV group.…”

“…17 In pandemic A/H1N1 influenza vaccine studies, the data are contrasting. In fact, several studies on the efficacy of MF59-adjuvanted 2009 pandemic A/H1N1 influenza vaccine (A/H1N1/Cal/09) suggested a lower rate of influenza seroconversion in HIV-infected individuals (36.4-69%) as compared with healthy donors ( > 79%), [18][19][20] even in patients with high CD4 T cell counts. 21 In contrast, other studies reported a good antibody response in successfully HAART-treated HIV patients.…”

2012/13 influenza vaccine effectiveness against hospitalised influenza A(H1N1)pdm09, A(H3N2) and B: estimates from a European network of hospitals

“…[267,268] These findings of reduced immunogenicity extend to adjuvanted vaccines (AS03 and MF-59) among HIV-positive compared to HIV-negative individuals. [269][270][271] Two systematic reviews conducted on the effectiveness of influenza vaccines among HIV-positive populations showed limited evidence of VE in this population and called for more data from RCT settings. [12,13] However, a recent RCT of TIV among HIV-infected adults in South Africa showed a vaccine efficacy of 76% and high levels of serological conversion.…”

Assessment of Antigen-Specific and Cross-Reactive Antibody Responses to an MF59-Adjuvanted A/H5N1 Prepandemic Influenza Vaccine in Adult and Elderly Subjects

“…Several clinical trials of A/H5N1 vaccines containing A/Vietnam/1194/2004 strain antigen have shown that, as well as decreasing the amount of antigenic material required per dose (7), the oil-in-water adjuvant MF59 (Novartis Vaccines and Diagnostics) increases the production of cross-reactive, neutralizing antibodies (13, 14, 18-20, 24, 28). The ability of MF59 to enhance antigenspecific and cross-reactive antibody responses has been demonstrated in vaccinees of all ages, including the elderly (2,12,33,34) and other high-risk populations (1,8,9,17,22,30,39).…”